Entrada Therapeutics, Inc. (TRDA) DCF Valuation

Valoración de DCF de Entrada Therapeutics, Inc. (TRDA)

US | Healthcare | Biotechnology | NASDAQ
Entrada Therapeutics, Inc. (TRDA) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Entrada Therapeutics, Inc. (TRDA) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Explore la perspectiva financiera de Entrada Therapeutics, Inc. (TRDA) con nuestra calculadora DCF fácil de usar! Ingrese sus proyecciones para el crecimiento, los márgenes y los gastos para calcular el valor intrínseco de Entrada Therapeutics, Inc. (TRDA) e informar sus decisiones de inversión.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 129.0 129.0 129.0 129.0 129.0 129.0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -11.7 -26.3 -50.0 -95.4 -.3 103.1 103.1 103.1 103.1 103.1
EBITDA, % 100 100 100 100 -0.24881 79.95 79.95 79.95 79.95 79.95
Depreciation .1 .3 1.1 1.9 2.8 103.8 103.8 103.8 103.8 103.8
Depreciation, % 100 100 100 100 2.2 80.44 80.44 80.44 80.44 80.44
EBIT -11.8 -26.7 -51.1 -97.2 -3.2 102.6 102.6 102.6 102.6 102.6
EBIT, % 100 100 100 100 -2.45 79.51 79.51 79.51 79.51 79.51
Total Cash 16.8 39.0 291.1 45.2 352.0 129.0 129.0 129.0 129.0 129.0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 5.9
Account Receivables, % 100 100 100 100 4.56
Inventories .0 .0 .0 .0 .0 103.2 103.2 103.2 103.2 103.2
Inventories, % 100 100 100 100 0 80 80 80 80 80
Accounts Payable .7 1.6 .7 6.0 3.3 103.9 103.9 103.9 103.9 103.9
Accounts Payable, % 100 100 100 100 2.54 80.51 80.51 80.51 80.51 80.51
Capital Expenditure -.6 -2.3 -4.6 -2.9 -5.6 -1.1 -1.1 -1.1 -1.1 -1.1
Capital Expenditure, % 100 100 100 100 -4.35 -0.8703 -0.8703 -0.8703 -0.8703 -0.8703
Tax Rate, % 155.45 155.45 155.45 155.45 155.45 155.45 155.45 155.45 155.45 155.45
EBITAT -10.8 -26.5 -50.0 -89.9 1.8 78.1 78.1 78.1 78.1 78.1
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -10.6 -27.6 -54.4 -85.6 -9.6 79.7 180.8 180.8 180.8 180.8
WACC, % 5.25 5.29 5.28 5.26 4.82 5.18 5.18 5.18 5.18 5.18
PV UFCF
SUM PV UFCF 682.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 184
Terminal Value 5,797
Present Terminal Value 4,503
Enterprise Value 5,185
Net Debt 1
Equity Value 5,185
Diluted Shares Outstanding, MM 33
Equity Value Per Share 156.87

What You Will Get

  • Real TRDA Financial Data: Pre-filled with Entrada Therapeutics’ historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See Entrada Therapeutics’ intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Comprehensive Entrada Data: Gain access to reliable pre-loaded historical performance metrics and future forecasts.
  • Adjustable Forecast Parameters: Modify highlighted fields such as WACC, growth rates, and profit margins.
  • Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
  • User-Friendly Dashboard: Clear charts and summaries designed to help visualize your valuation outcomes.
  • Suitable for All Users: An intuitive layout tailored for investors, CFOs, and consultants alike.

How It Works

  1. Step 1: Download the Excel file for Entrada Therapeutics, Inc. (TRDA).
  2. Step 2: Review Entrada’s pre-filled financial data and projections.
  3. Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Observe the DCF model update in real-time as you modify your assumptions.
  5. Step 5: Evaluate the outputs and leverage the results for your investment choices.

Why Choose This Calculator for Entrada Therapeutics, Inc. (TRDA)?

  • User-Friendly Interface: Perfectly crafted for both novices and seasoned professionals.
  • Customizable Inputs: Adjust parameters effortlessly to suit your specific analysis.
  • Real-Time Feedback: Observe immediate updates to Entrada Therapeutics' valuation as you modify inputs.
  • Pre-Loaded Data: Comes equipped with Entrada’s current financial metrics for swift evaluations.
  • Relied Upon by Experts: A go-to tool for investors and analysts aiming to make educated decisions.

Who Should Use This Product?

  • Biotech Students: Understand drug development processes and apply them using real-world data.
  • Researchers: Integrate advanced therapeutic models into academic studies or clinical research.
  • Investors: Evaluate your investment strategies and analyze market trends for Entrada Therapeutics, Inc. (TRDA).
  • Industry Analysts: Enhance your analysis with a comprehensive, customizable valuation model tailored for biotech companies.
  • Pharmaceutical Entrepreneurs: Learn how established biotech firms like Entrada Therapeutics are assessed and valued.

What the Template Contains

  • Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Entrada Therapeutics, Inc. (TRDA).
  • Real-World Data: Entrada’s historical and projected financials preloaded for in-depth analysis.
  • Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
  • Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
  • Dashboard with Visual Outputs: Visualizations including charts and tables for clear, actionable results.

No products were found matching.